Transcutaneous electrical nerve stimulation for Sjogren's disease (VNS for Sjogren's disease)

未提供0 个研究点目标入组 30 人开始时间: 待定

适应症

试验速览

暂无简介。

•Patients with Sjogren's syndrome who are receiving outpatient care or hospitalized at Hokkaido University Hospital, Nagasaki University Hospital, or Tsukuba University between the date of implementation approval and January 31, 2028

•Patients meeting any of the following criteria will be excluded from the study:
•Patients with a history of progressive brain lesions (or progressive cerebral disorders).
•Patients concurrently receiving Vagus Nerve Stimulation (VNS) therapy.
•Patients with a history of severe cardiovascular disease.
•Patients with a history of hypersensitivity to glycerin.
•Patients who are pregnant or breastfeeding.
•Patients with skin hypersensitivity who have a history of dermatological reactions to metals or other substances.
•Patients with difficulty in oral intake.
•Patients with an implanted cardiac pacemaker or an implantable cardioverter-defibrillator (ICD).
•Patients using immunosuppressants (such as glucocorticoids, methotrexate, azathioprine, mycophenolic acid, tacrolimus, or cyclosporine) or hydroxychloroquine.
•Any other patients deemed unsuitable for the study by the Principal Investigator or Sub-investigator.

发起方

未提供